Navigation Links
Cadence Pharmaceuticals Reports First Quarter 2013 Financial Results
Date:5/2/2013

he end-user customer.  Cadence recognized this deferred revenue during the period as it determined it had obtained sufficient product return history as of January 1, 2013, to reasonably estimate future wholesaler returns. As a result, the company recorded a one-time adjustment during the three months ended March 31, 2013, to recognize deferred revenue on previously shipped product, resulting in additional net revenue of $2.6 million and cost of sales of $0.9 million, for a net gross margin impact of $1.7 million.

For the three months ended March 31, 2013, Cadence reported a net loss of $1.4 million, or $0.02 per share, compared to a net loss of $22.7 million, or $0.27 per share, for the comparable period in 2012. Included in the company's net loss for the three months ended March 31, 2013, was a gain of $7.7 million Cadence recorded on the waiver, termination and sale of its Incline assets in January 2013, for which the company received cash payments totaling $14.6 million. Excluding the $7.7 million gain from the Incline transaction, and the $1.7 million gross margin impact from the change in the company's revenue recognition accounting estimate, Cadence's net loss for the three months ended March 31, 2013, was $10.8 million, or $0.13 per share.

Gross margin for the three months ended March 31, 2013, was 65%, compared to 47% for the comparable period in 2012. The increase in margin was primarily a result of higher freight costs incurred during the first quarter of 2012 that were not incurred in 2013, the impact of price increases implemented in July 2012 and January 2013, and a one-time credit of $0.3 million recorded during the three months ended March 31, 2013, in connection with the termination of the company's supply agreement with Baxter. Operating expenses, including patent amortization, decreased $2.0 million for the three months ended March 31, 2013, to $23.4 million, from $25.4 million for the same period in 2012. This decrease in
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Cadence Pharmaceuticals Reports Second Quarter 2012 Financial Results
2. Cadence Pharmaceuticals To Present At The Deutsche Bank Securities, Inc. 37th Annual Health Care Conference In Boston On May 8, 2012
3. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2011 Financial Results on March 12, 2012
4. Valeant Pharmaceuticals Announces Extension of the Expiration Date for Its Previously Announced Tender Offer for All Outstanding Shares of Common Stock of Obagi Medical Products, Inc.
5. VentiRx Pharmaceuticals Appoints James Kyle Bryan, M.D. as Chief Medical Officer
6. Aurigenes Collaboration Programs with Endo Pharmaceuticals Reach Important Milestones
7. Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer
8. Next Silicon Valley BioTalks Tackles “Is EDC Becoming a Commodity?” at Onyx Pharmaceuticals HQ
9. Global Nuclear Medicine / Radiopharmaceuticals Market worth $5.55 Billion by 2017
10. US Radiopharmaceuticals (USR) Awards Contract to Von Gahlen International for New Technetium-99m Generator Production Line Using Low Enriched Uranium Molybdenum-99
11. Anthera Pharmaceuticals Reports 2012 Fourth Quarter And Fiscal Year Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... Following the successful launch of On ... to introduce its new product and demonstrate its potential ... Launched in September, Formedix On Demand Services is the ... automation tools. For the first time, these market-leading tools ... introducing Formations – a revolutionary new token-based payment system ...
(Date:10/31/2014)... 31, 2014 The report "Dairy ... Formulation (Plain, Flavored, Sweetened, Unsweetened), Channel (Supermarket, Health ... Trends & Forecast to 2018," defines and segments ... and forecast of revenue and volume for plant-based ... projected to reach $14 Billion by 2018 with ...
(Date:10/31/2014)... 2014 ENVIRON , an ... today that Dr. Harvey Clewell III has rejoined ... work closely with senior professionals in ENVIRON’s Health ... serve at The Hamner Institutes for Health Sciences ... where he is Director, Center for Human Health ...
(Date:10/31/2014)... 31, 2014  Tavistock Development Co. (TDC), a ... celebrated the groundbreaking of the GuideWell Innovation Center ... The 92,000-square-foot, three-story facility is the first ... designed specifically for life sciences, health innovation, ... the 650-acre Lake Nona Medical City, near the ...
Breaking Biology Technology:Formedix to Introduce "Revolutionary" Clinical Trial Automation Software with Learning Webinar 2Dairy Alternative Beverage Market Projected to Reach $14 Billion by 2018 - Report by MarketsandMarkets 2Dairy Alternative Beverage Market Projected to Reach $14 Billion by 2018 - Report by MarketsandMarkets 3Dairy Alternative Beverage Market Projected to Reach $14 Billion by 2018 - Report by MarketsandMarkets 4Internationally recognized health scientist Dr. Harvey Clewell renews association with ENVIRON 2Internationally recognized health scientist Dr. Harvey Clewell renews association with ENVIRON 3GuideWell Innovation Center Groundbreaking Hosted by Tavistock Development Company at Lake Nona Medical City 2GuideWell Innovation Center Groundbreaking Hosted by Tavistock Development Company at Lake Nona Medical City 3
... silicon transistors in your computer may be replaced in ten ... scientists at the University of Gothenburg are hoping they ... Silicon is subject to certain limitations, and industry is ... sales of over USD 200 billion, and this means that ...
... Mass. , June 1 Merrimack Pharmaceuticals today announced that it will present ... Mulroy , President and Chief Executive Officer, will provide a company overview at 11:00am EDT ... , New York . , , , ... Merr i mack , ...
... LAKE CITY , June 1 Glycosan BioSystems ... gaining regulatory approval within the European Union for the use ... autologous adipose derived cells in reconstruction and aesthetic plastic surgery ... Mark as an implantable medical device.  HyStem-Rx will ...
Cached Biology Technology:Faster computers with nanotechnology 2Merrimack Pharmaceuticals to Present at the Jefferies 2010 Global Life Sciences Conference 2Glycosan BioSystems Seeks CE Mark in the European Union for HyStem-Rx, a Unique, Implantable Scaffold for Tissue Engineering 2
(Date:10/29/2014)... household and industrial products are in the environment – ... of them, scientists have yet to determine whether they ... toward doing that by estimating which substances people are ... in the ACS journal Environmental Science & Technology ... the risks to human health of any given substance ...
(Date:10/29/2014)... New York City on September 19, 2014, leading geneticist ... Professor of Genome Sciences and Medicine at the University ... Philosophy of Tel Aviv University, was awarded the 2014 ... addition to her honorary degree from TAU, Prof. King ... of Medicine, and for the past 18 years she ...
(Date:10/29/2014)... news release is available in German . ... like another: Gabriela Cabral and Peter Schlögelhofer at the ... Vienna and the Medical University of Vienna dived into ... revealed that these plants display an inversion of the ... in the scientific journal Nature Communications . , ...
Breaking Biology News(10 mins):Geneticist and humanitarian: Prof. Mary-Claire King receives Lasker Award 2Meiotic cell division 'the other way round' 2
... new quarterly newsletter for academic librarians and information professionals. ... developments at OUP and across the publishing world. ... and member of the Editorial Team said: ,After careful ... developed a strong and broad source of information for ...
... has been largely overlooked by the public until now. ... of 157 scientists (the Nasonia Genome Working Group) ... University of Rochester, and Stephen Richards at the Genome Sequencing ... the genomes of three parasitoid wasp species. The genomes reveal ...
... 500,000 funding for the Peninsula Dental School to pursue three ... was announced today. The first area of research will ... published evidence and the creation of new approaches to understanding ... will look at the use of virtual reality and psychological ...
Cached Biology News:Genome advances peril for pests 2Genome advances peril for pests 3Genome advances peril for pests 4University of Plymouth invests in dental research 2
BD BioCoat Fibronectin 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of human fibronectin....
... a positive selection for creating baculovirus recombinants ... insect cells. The kit improves on the ... eliminating the time-consuming steps of plaque purification. ... with a portion of the essential open ...
... General description: Dish uses include large-scale colony-counting ... with PBA Flexys TM automated colony ... is a new product number, created to ... no availability yet, please order under the ...
Mouse monoclonal [7B9] to beta II Tubulin ( Abpromise for all tested applications). Antigen: Synthetic peptide, CEEEEGEDEA found at the c-terminus of beta II tubulin. Entrez GeneID: 10383 ...
Biology Products: